Skip to main page content (V体育官网入口)
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. VSports app下载.

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

Review
. 2020 Jul;10(7):922-934.
doi: 10.1158/2159-8290.CD-19-1446. Epub 2020 Jun 12.

"VSports app下载" Targeting MET Dysregulation in Cancer

Gonzalo Recondo  1 , Jianwei Che  2   3 , Pasi A Jänne  4   5 , Mark M Awad  4
Affiliations
Review

Targeting MET Dysregulation in Cancer

Gonzalo Recondo et al. Cancer Discov. 2020 Jul.

Abstract

Aberrant MET signaling can drive tumorigenesis in several cancer types through a variety of molecular mechanisms including MET gene amplification, mutation, rearrangement, and overexpression. Improvements in biomarker discovery and testing have more recently enabled the selection of patients with MET-dependent cancers for treatment with potent, specific, and novel MET-targeting therapies. We review the known oncologic processes that activate MET, discuss therapeutic strategies for MET-dependent malignancies, and highlight emerging challenges in acquired drug resistance in these cancers. SIGNIFICANCE: Increasing evidence supports the use of MET-targeting therapies in biomarker-selected cancers that harbor molecular alterations in MET. Diverse mechanisms of resistance to MET inhibitors will require the development of novel strategies to delay and overcome drug resistance. VSports手机版.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

G. R. Consultant/advisory board : Amgen, Pfizer, Roche V体育ios版. Travel grants: Pfizer, AstraZeneca.

J VSports最新版本. C. Consultant: Soltego and Kymera Therapeutics. Shareholder: M3 bioinformatics & technology Inc.

P. A. J V体育平台登录. Consultant: AstraZeneca, Boehringer Ingelheim, Pfizer, Merrimack Pharmaceuticals, Roche/Genentech, Chugai Pharmaceuticals, Acea Biosciences, Ignyta, LOXO Oncology, Eli Lilly pharmaceuticals, Araxes pharmaceuticals, SFJ Pharmarceuticals, Voronoi, Daiichi Sankyo, Biocartis, Novartis, Takeda Oncology. Stock Ownership: Gatekeeper Pharmaceuticals, LOXO Oncology, Sanofi. Research Funding: Astellas Pharmaceuticals, AstraZenenca, Daiichi Sankyo, PUMA, Eli Lilly pharmaceuticals, Boehringer Ingelheim, Takeda Oncology, Revolution Medicines. Patents, Royalties, Other Intellectual Property: LabCorp.

M. M. A: Consultant/advisory board: Bristol-Myers Squibb, AstraZeneca, Achilles, AbbVie, Neon, Maverick, Nektar, Hegrui, Syndax, Gritstone. Institutional research funding: from Bristol-Myers Squibb, AstraZeneca, Lilly, Genentech VSports注册入口.

Figures

Figure 1.
Figure 1.. Mechanisms of MET oncogenic activation.
(A) MET activation is initiated after ligand binding of the hepatocyte growth factor (HGF) to the SEMA domain to the extracellular portion of the MET receptor, inducing receptor dimerization and phosphorylation of the intracellular domain leading to downstream signaling of several pathways. The E3 ubiquitin ligase CBL binds to reside Y1003 in the juxtamembrane domain (encoded in part by exon 14), resulting in receptor ubiquitination and degradation. MET exon 14 alterations including mutations or deletions in splicing regulatory sites, leading to exon skipping, deletion of a portion of the juxtamembrane domain, impaired CBL binding, decreased MET turnover, and ongoing oncogenic downstream pathway signaling. (B) Point mutations in the tyrosine kinase domain result in ligand-independent MET activation through autophosphorylation of the tyrosine kinase domain, conveying sustained oncogenic downstream pathway signaling. (C) Focal MET amplification leads to higher levels of MET transcription and MET expression. MET amplification (high MET/CEP7 ratio) differs from chromosome 7 polysomy or copy number gain in which the entire chromosome is duplicated (low MET/CEP7 ratio). Focal MET amplification and, consequently high MET expression, leads to enhanced ligand-independent oncogenic signaling by receptor auto-dimerization or oligomerization and auto-phosphorylation. (D) Gene rearrangements involving the MET tyrosine kinase domain result in fusion proteins that typically self-dimerize in a ligand-independent manner, leading to phosphorylation of the tyrosine kinase domain.
Figure 2.
Figure 2.. Mechanisms of resistance to MET tyrosine kinase inhibitors in MET exon 14 mutant lung cancer.
Crystal modelling of the MET kinase domain and binding of MET tyrosine kinase inhibitors (green). The figure displays the position of frequently mutated residues within the MET kinase domain including G1163 (red), D1228 (purple), Y1230 (blue), L1195 (yellow), and F1200 (orange) that confer acquired resistance to MET TKIs. Panel A displays interaction of the type Ia MET TKI crizotinib (PDB Ref: 2WGJ) with commonly mutated residues that confer resistance to crizotinib like G1163R, D1228X and Y1230X mutations. Panel B shows the interaction of the type Ib MET inhibitor savolitinib analog (PDB Ref: 3ZC5) with resistance mutations including D1228X and Y1230X, but the interaction with the kinase domain is not predicted to be affected by the G1163R solvent front mutation. In panel C, the type II MET TKI merestinib (PDB Ref: 4EEV) is simulated bound to the kinase domain and displays the interaction of type II MET inhibitors with key residues that can cause resistance to these compounds like L1195F/V and F1200L.
See this image and copyright information in PMC

References

    1. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth J Cell Biol. United States; 1992;119:629–41. - PMC - PubMed
    1. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud Nature. England; 1995;376:768–71. - PubMed
    1. Huh C-G, Factor VM, Sanchez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair Proc Natl Acad Sci U S A. United States; 2004;101:4477–82. - PMC - PubMed
    1. Okunishi K, Dohi M, Nakagome K, Tanaka R, Mizuno S, Matsumoto K, et al. A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function J Immunol. United States; 2005;175:4745–53. - PubMed
    1. Benkhoucha M, Santiago-Raber M-L, Schneiter G, Chofflon M, Funakoshi H, Nakamura T, et al. Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells Proc Natl Acad Sci U S A. United States; 2010;107:6424–9. - PMC - PubMed

Publication types

Substances